Bexorg

Bexorg’s adaptable platform enables perfusion of whole human and porcine brains.

The page lists recent press coverage of Bexorg’s technology.

Bexorg invites users to join.

Spun out of Yale University, Bexorg is revolutionizing how CNS medicines are discovered and developed.

The page provides contact information for Bexorg.

The first-ever AI and whole-human brain drug discovery platform built to end CNS clinical failure

Bexorg secures up to **$28.3 million** from **ARPA-H** to develop **human brain translational pharmacology** tools for central nervous system (CNS) drug discovery. The funding supports research aimed at improving CNS drug development by bridging gaps between preclinical models and human clinical outcomes. The project focuses on enhancing predictive accuracy for CNS therapies, addressing a critical bottleneck in neuroscience drug innovation.

Oct 2026GlobeNewswireNews article

Bexorg appoints **Bruce Car, Ph.D.** as **Chief Scientific Officer** and **Michael Fenn, Ph.D.** as **Chief Business Officer** to strengthen its executive leadership. The hires follow the company’s focus on advancing its biotech pipeline and scaling commercial operations. Both executives bring extensive experience in pharmaceutical development and business strategy.

Jul 2026GlobeNewswireNews article

Bexorg secures funding from The Michael J. Fox Foundation to develop biomarkers that validate TRPML1 as a therapeutic target for Parkinson’s disease. The grant supports research into identifying measurable indicators to assess drug engagement in clinical trials. TRPML1 shows potential as a key focus for new treatment approaches in Parkinson’s therapy.

Jan 2026BioSpaceNews article

Bexorg appoints **Sean Murphy, Ph.D.** as its new **Chief Technology Officer (CTO)** to bolster its leadership team. The move follows the company’s focus on advancing its technology-driven solutions in the biopharmaceutical sector. Murphy brings extensive expertise in drug discovery and computational biology, aligning with Bexorg’s mission to accelerate innovation in life sciences.

Nov 2025GlobeNewswireNews article